Copyright
©The Author(s) 2018.
World J Hepatol. Dec 27, 2018; 10(12): 911-923
Published online Dec 27, 2018. doi: 10.4254/wjh.v10.i12.911
Published online Dec 27, 2018. doi: 10.4254/wjh.v10.i12.911
ANA | Variably expressed with ASMA in type 1 AIH |
Heterogenous antigen profile | |
No single staining pattern is pathognomonic for diagnosis of AIH | |
Most useful when found with ASMA (diagnostic accuracy 74%)[20] | |
ASMA | Marker of type 1 AIH along with ANA |
Reacts to several cytoskeletal elements, especially F-actin. | |
ELISA against F-actin as the substrate can be used instead of indirect immunofluorescence but may miss the diagnosis in 15% to 20% of cases[20] | |
Anti-SLA/LP | Only disease specific antibody with specificity of 99% for AIH |
Present in only 15% patients with AIH in the United States | |
Known to have a defined antigen, SEPSECS. ELISA is the preferred methodology of testing | |
Closely associated with HLA DRB1*03 and Anti-Ro/SSA | |
Have prognostic value as it is associated with severe disease, higher risk of relapse and need for lifelong treatment | |
Anti-LKM1 | Serologic marker for type 2 AIH. |
CYP2D6 is the target antigen. Shares homology with hepatitis C virus antigen | |
Present mainly in children, worldwide. Rare in adults in the United States (< 4%) | |
Associated with HLA DRB*07 | |
Atypical pANCA | Common in type 1 AIH, and absent in type 2 AIH |
Associated with PSC, UC |
- Citation: Lowe D, John S. Autoimmune hepatitis: Appraisal of current treatment guidelines. World J Hepatol 2018; 10(12): 911-923
- URL: https://www.wjgnet.com/1948-5182/full/v10/i12/911.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i12.911